Intuitive Machines partners with Houston college for workforce training

space training

Intuitive Machines, Rhodium Scientific and San Jacinto College will partner to train future workers for space-based pharma recovery. Photo courtesy Intuitive Machines.

Intuitive Machines, a Houston-based space technology, infrastructure and services company, has forged a partnership with San Jacinto College to develop a program for training workers to handle biopharmaceutical materials delivered to Earth on Intuitive Machines’ re-entry vehicle.

Intuitive Machines is working with biotech company Rhodium Scientific on the project. Rhodium, also based in Houston, is developing biomanufacturing payloads for Intuitive Machines’ re-entry vehicle.

“Delivering life-improving pharmaceuticals from orbit is only valuable with reliable recovery and processes on Earth,” Tim Crain, chief technology officer at Intuitive Machines, said in a news release. “That requires more than a spacecraft — it demands the workforce, facilities, and regulatory alignment to support safe, repeatable operations. San Jacinto College has the credibility and technical depth to make this vision a reality.”

San Jacinto College provides training certified by the National Institute for Bioprocessing Research and Training. Christopher Wild, assistant vice chancellor and vice president of biotechnology at San Jacinto College, said that with this certification and the college’s presence at Houston Spaceport, the school “is uniquely positioned to train the workforce needed (for) commercial space-based pharma recovery.”

The first-phase grant supporting Intuitive Machines’ Earth re-entry program will culminate in a full-scale mockup tailored to real payloads and use cases in early 2026.

Intuitive Machines said the collaborations with San Jacinto College and Rhodium “aim to align future landing infrastructure, research opportunities, and funding pathways that deliver lasting economic impact from space.”

From Your Site Articles
San Jacinto College's new Center for Biotechnology at the Generation Park Campus is expected to be completed early next year. Photo courtesy of San Jacinto College

Houston-area college breaks ground on new biotechnology program, launches curriculum

coming soon

San Jacinto College and McCord Development Inc. broke ground on the new Center for Biotechnology at the Generation Park Campus in Northeast Houston.

The 4,000-square-foot, state-of-the-art facility is slated to allow for more hands-on training within simulated environments and will allow students to earn associate of applied science degrees in biomanufacturing technology, as well as credentials for those already in the workforce. It's scheduled to be completed in the first quarter of 2025.

“The Center and the overall components of the Biotechnology program will play a vital role in meeting the growing demand for skilled professionals in the biotechnology sector,” Brenda Hellyer, chancellor of San Jacinto College, says in a statement.

“We are committed to equipping our students with the skills and knowledge necessary for success in the dynamic biopharmaceutical industry," she continues. "Our vision is to not only meet the workforce needs of today but will also shape the future of biotechnology education and training in our region.”

San Jacinto College and McCord Development Inc. celebrated the groundbreaking of the new Center for Biotechnology at the Generation Park Campus in Northeast Houston. Photo courtesy of San Jacinto College

The new Center for Biotechnology curriculum is in partnership with the Ireland-based National Institute for Bioprocessing Research and Training. It is the only NIBRT-licensed training in the Southwest and Southeast region.

At the groundbreaking, San Jacinto College celebrated the ribbon-cutting for the Biomanufacturing Training Program at the South Campus, the first of the college's comprehensive biotechnology offerings.

The Biomanufacturing Training Program will be a customizable two-week hybrid program that combines theoretical teachings with hands-on experience.

“This program is designed to provide a seamless entry into the field for new professionals, with a focus on practical experience and exposure to industry practices,” Christopher Wild, executive director of San Jacinto College Center for Biotechnology, added in a statement.

The new center is part of Generation Park, a 4,300-acre master-planned development in Northeast Houston. In late 2022, San Jac and McCord, which is developing Generation Park, shared that they had signed a memorandum of understanding with the NIBRT to launch the program and center.

At the time, San Jacinto College was slated to be the institute’s sixth global partner and second U.S. partner.

Last summer, McCord also revealed plans for its 45-acre biomanufacturing campus at Generation Park.
Houston's San Jacinto College is launching a biotechnology program in early 2024 to be housed in the Center for Biotechnology in Generation Park. Rendering courtesy of McCord

Houston-area college shares more details on new biotechnology program, center

coming soon

Houston's San Jacinto College will roll out a new biotechnology program in early 2024 as it gets closer to its goal of launching the Center for Biotechnology in Generation Park.

In partnership with the Ireland-based National Institute for Bioprocessing Research and Training, the licensed training curriculum will offer regional biopharmaceutical training at the college's South Campus starting in January.

Initially, the 90-hour hybrid training program will provide opportunities for participants to gain experience with "all aspects of biomanufacturing, specialized instrumentation and equipment training, and advanced techniques," according to a statement. Students will earn an onboarding certificate that will help them enter the field.

The college then plans to open the Center for Biotechnology, developed by McCord Development Inc., at its Generation Park Campus in the first quarter of 2025. The state-of-the-art facility is slated to allow for more hands-on training within simulated environments, and will allow students to earn associate of applied science degrees in biomanufacturing technology, as well as credentials for those already in the workforce.

“The biomanufacturing industry is seeing substantial growth in the Greater-Houston area,” Christopher Wild, executive director for the San Jacinto College Center for Biotechnology, says in a statement. “The College’s partnership to offer NIBRT’s premier, industry-leading training right here in the Houston-area represents a firm commitment to bolstering the biomanufacturing workforce pipeline which will help position the region for continued growth.”

The center will also offer programs that are customizable to industry partners' needs, according to a statement, and will provide cost-effective training for new hires. It will be the only NIBRT-licensed training in the Southwest and Southeast region.

“The NIBRT team have been very impressed by San Jacinto’s excellent track record in developing workforce programmes for the Greater Houston Region across a broad range of industrial sectors," Darrin Morrissey, CEO of NIBRT, says in a statement. We are very much looking forward to working with the San Jacinto team to deliver world class biopharma training programs to their students."

The new center is part of Generation Park, a 4,300-acre master-planned development in Northeast Houston. In late 2022, San Jac and McCord, which is developing Generation Park, shared that they had signed a memorandum of understanding with the NIBRT to launch the program and center.

At the time, San Jacinto College was slated to be the institute’s sixth global partner and second U.S. partner.

Over the summer, McCord also revealed plans for its 45-acre biomanufacturing campus at Generation Park.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings